News Update on Psoriasis Research: Sep – 2019

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening

There are many articles and reports in recent months concerning comorbidities and risks that have an effect on skin {disease|disease of the skin|skin disorder|skin problem|skin condition} patients additionally to their underlying disease. This piece reviews the present literature and begins to deal with what ought to be finished this new info by change the practician concerning what health screening tests, preventative exams, and referrals ought to be thought of during this population. [1]

Severe Psoriasis – Oral Therapy with a New Retinoid

Ro 10–9359 could be a retinoic acid spinoff, selected  for study thanks to a much better tolerance than retinoic acid, shown in animal experiments. Doses of twenty five mg b.i.d., 25 mg t.i.d. and fifty mg b.i.d. were administered orally to twenty seven patients tormented by severe chronic generalized skin disease. The clinical efficaciousness was evaluated by means that of a replacement index, skin disease space and severity index (PASI) supported severity and area of psoriatic lesions. At doses of twenty five mg t.i.d. or 50 mg b.i.d. Ro 10–9359 proven to be an especially potent antipsoriatic drug. A over ninetieth reduction of psoriatic lesions may well be seen in ten patients out of twenty when 4–8 weeks of treatment. This smart impact lasted regarding five weeks when treatment. facet effects were frequent, however principally delicate and utterly reversible when termination of treatment. [2]

Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation

An association between fatness and disease of the skin has been according. For a range of reasons, weighty persons with disease of the skin square measure usually tougher to treat. we tend to sought-after to review the literature on fatness and disease of the skin and to debate effectuality and safety knowledge that would be utilised by clinicians WHO square measure creating treatment choices for weighty persons with disease of the skin. we tend to performed a literature review victimization the terms “obesity and disease of the skin” and “metabolic syndrome and psoriasis.” proof from relevant literature was evaluated and classified in keeping with the factors of Shekelle et al (published 1999). varied reports cite AN association between fatness and disease of the skin. [3]

Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay

Because development of reliable biomarkers in skin condition and atopic eczema has lagged behind therapeutic progress, we tend to created a blood-based check to fill the void in objective strategies obtainable for medicine assessments. Our novel interleukin-19 (IL-19) bioassay was at first tested to see concentrations of IL-19 blood serum levels, then correlate with the skin condition activity and severity index (PASI) in skin condition, and therefore the skin condition space and severity index (EASI) in atopic eczema. Not solely was IL-19 augmented in skin condition and correlate to PASI, however ixekizumab administration junction rectifier to speedy, sustained IL-19 decreases to traditional levels, with decreases at 2-weeks correlating with PASI improvement at 16-weeks. [4]

The Relationship between Psoriasis and Serum Levels of Vitamin D

Introduction: skin condition could be a common chronic inflammatory skin condition with advanced pathophysiology. The role of fat-soluble vitamin has recently arisen in several skin and general diseases as well as skin condition through its changed result of inflammatory and medical specialty mechanisms. many studies have incontestible its effects on keratinocytes’ proliferation and differentiation, body covering system, control the microorganism flora and therefore the response to infective diseases. [5]

Reference

[1] Kimball, A.B., Gladman, D., Gelfand, J.M., Gordon, K., Horn, E.J., Korman, N.J., Korver, G., Krueger, G.G., Strober, B.E., Lebwohl, M.G. and Foundation, N.P., 2008. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. Journal of the American Academy of Dermatology, 58(6), (Web Link)

[2] Fredriksson, T. and Pettersson, U., 1978. Severe psoriasis–oral therapy with a new retinoid. Dermatology, 157(4), (Web Link)

[3] Bremmer, S., Van Voorhees, A.S., Hsu, S., Korman, N.J., Lebwohl, M.G., Young, M., Bebo Jr, B.F., Blauvelt, A. and Foundation, N.P., 2010. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology, 63(6), pp.1058-1069. (Web Link)

[4] Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay
Robert J. Konrad, Richard E. Higgs, George H. Rodgers, Wenyu Ming, Yue-Wei Qian, Nicoletta Bivi, Justin K. Mack, Robert W. Siegel & Brian J. Nickoloff
Scientific Reportsvolume 9, Article number: 5211 (2019) (Web Link)

[5] Tajjour, R., Baddour, R., Redwan, F. and Hassan, F. (2018) “The Relationship between Psoriasis and Serum Levels of Vitamin D”, Journal of Advances in Medicine and Medical Research, 26(3), (Web Link)